No validated molecular target identified for SRD-005

SRD-005 is a gene therapy candidate currently under development by Sardocor, a subsidiary of Medera Inc., aimed at treating pulmonary fibrosis. While the drug is part of a pipeline that utilizes adeno-associated virus (AAV) vectors to deliver therapeutic genetic material, the specific molecular target or the identity of the gene being delivered has not been publicly validated or disclosed in clinical literature. The therapeutic objective of SRD-005 is to address the underlying pathology of fibrotic lung diseases, potentially by modulating pathways involved in extracellular matrix deposition or alveolar repair. As a novel gene therapy, it represents a specialized approach to treating conditions like idiopathic pulmonary fibrosis, where current treatment options are limited. The lack of a validated molecular target in public records reflects the early-stage or proprietary nature of the program within the Sardocor cardiovascular and pulmonary pipeline.

Other names

Undisclosed target for SRD-005Unknown target for SRD-005Sardocor SRD-005 target

The mechanism of action for SRD-005 involves the delivery of a therapeutic gene via an adeno-associated virus (AAV) vector to treat pulmonary fibrosis, although the specific molecular target or gene identity has not been publicly disclosed.